Ingredient definition and characterization
NoQuestionsAI checks whether identity, composition, specifications, and analytical support describe the notified substance with sufficient precision.
Risk Assessment
See where your GRAS dossier may face questions.
NoQuestionsAI uses NOQIntelligence™ to evaluate dossier completeness, evidentiary support, internal consistency, and likely FDA-facing review friction. The result is a practical gap analysis for improving the record before submission pressure begins.
Notification readinessGap analysis
Identity and specifications
Strong
Exposure support
Review
Safety rationale
Gap
NOQIntelligence™ matches dossier content against relevant GRAS precedent and recurring review patterns.
Risk is rarely isolated to one missing document.
GRAS notification readiness depends on how identity, manufacturing, specifications, intended use, exposure, safety, and regulatory history work together. NoQuestionsAI evaluates those dependencies and shows where an apparently complete record may still invite questions.
Process controls and dossier consistency
NoQuestionsAI looks for gaps between the manufacturing narrative, specifications, impurities, process controls, and the substance evaluated for safety.
Intended use and dietary exposure support
NoQuestionsAI evaluates whether food categories, use levels, intake assumptions, and cumulative exposure logic form a coherent basis for review.
Evidence strength and bridging logic
NoQuestionsAI identifies unsupported conclusions, missing study context, uncertain read-across, and places where the safety narrative may need stronger explanation.
A prioritized view of what needs attention.
NoQuestionsAI does more than assign a general risk label. The Risk Assessor connects each signal to the affected dossier section, explains why the issue matters, and identifies the next work needed to strengthen the record.
- A section-by-section gap analysis
- Prioritized risk drivers and unresolved assumptions
- Likely clarification or pushback areas
- Relevant NOQIntelligence™ precedent and source matches
- Recommended actions before expert or FDA-facing review
Evaluate whether an existing GRAS record is ready to convert.
A self-affirmed GRAS conclusion may contain substantial scientific support without being organized for FDA notification. NoQuestionsAI evaluates how closely the existing record aligns with a notification-ready dossier and where additional substantiation or restructuring may be required.
- Map the existing recordNoQuestionsAI organizes the self-affirmed GRAS record against the structure and evidence expectations of an FDA GRAS notification.
- Identify notification gapsNOQIntelligence™ highlights missing support, inconsistent claims, weak exposure logic, and areas where the record may not yet withstand external review.
- Characterize conversion readinessNoQuestionsAI provides a directional readiness assessment based on completeness, evidence quality, internal consistency, and relevant regulatory precedent.
- Prioritize remediationThe assessment translates risk signals into an ordered work plan for strengthening the dossier before notification or expert review.
Turn uncertainty into an actionable dossier plan.
NoQuestionsAI provides a decision-support assessment, not a legal determination or guarantee of FDA response. Qualified regulatory, scientific, and legal professionals should review the final GRAS basis and notification strategy.
Get Started